Moreover, recent evidence demonstrate that CDK4/6 inhibitors enhance tumor immunogenicity through potential elimination of tumor cells, providing an explanation for new combination therapies involving CDK4/6 inhibitors and immunotherapy.56 Here, CDK4 is linked to neoplasm.